Work

PRMT5-mediated metabolic reprogramming drives lactate-dependent PD-L1 activation and immune evasion in colorectal cancer

Year: 2026
Type: article
Abstract: Patients with PRMT5-high colorectal cancer (PRMT5 hi CRC) exhibit poor prognosis, yet how PRMT5 coordinates metabolism and immune evasion remains unclear. Here, we demonstrate that elevated PRMT5 catalyzes symmetric dimethylation of pyruvate kinase M2 (PKM2), enhancing its active tetramer formation and glycolytic flux, leading to lactate accumulation. This lactate serves as a substrate for AARS2-mediated lactylation of centromere protein A (CENPA) at lysine 124. Lactylated CENPA shows enhanced affinity for KPNA2 facilitating its nuclear translocation where it acts as a transcriptional co-activator that interacts with the transcription factor YY1 to cooperatively upregulate programmed death-ligand 1 (PD-L1) expression. Consequently, elevated PD-L1 suppresses cytotoxic T-cell activity, promoting tumor immune evasion and accelerating CRC progression. Clinically, PRMT5 levels positively correlate with PD-L1 expression and predict unfavorable outcomes. Through high-throughput screening, we identify a potent compound that disrupts the PRMT5-PKM2 interaction. In vitro , this disruption synergizes with anti-PD-1 treatment to enhance immune-mediated tumor cell killing. Our findings reveal a novel PRMT5-PKM2-lactate-CENPA/YY1-PD-L1 axis linking metabolism to immune suppression, and nominate PRMT5-PKM2 interface as a potential therapeutic target to improve outcomes in PRMT5 hi CRC.
Language: English
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7237207003
FWCI:
Cites: 46
Cited by:
Related to: 10
Parts: 1